Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015
|
|
- Cecily Malone
- 5 years ago
- Views:
Transcription
1 Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015
2 Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as believe, will, may, estimate, continue, anticipate, intend, should, plan, might, approximately, expect, predict, could, potentially or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places throughout this presentation and the accompanying oral commentary and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates AFM13, AFM11 and AFM21, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the leading Risk Factors in Affimed s filings with the Securities and Exchange Commission. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management s beliefs and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. 2
3 Corporate facts Nasdaq: AFMD Affimed is developing immune cell engagers in immuno-oncology Leading edge technology platforms that Direct the immune system to eliminate tumor cells Target NK-cells or T-cells Clinical stage product candidates are unencumbered Leader in NK-cell-based approach Validation through partnerships with Amphivena/Janssen (JnJ) and support from The Leukemia & Lymphoma Society (LLS) Raised $97 million in IPO on Nasdaq and follow-on Cash and cash equivalents as of March 31, 2015: EUR 37.0 million (not including EUR ~33.2 million net proceeds from May 2015 follow-on) 3
4 Current pipeline and programs Global rights retained with 3 candidates Compound Disease Target Immune Cell Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Hodgkin Lymphoma AFM13 CD30 CD16A / NK-cell AFM11 CD19 CD3 / T-cell AFM21 EGFRvIII CD3/T-cell CD16A/NK-cell CD30+ Lymphoma Hodgkin Lymphoma Combination with CPIs* Hodgkin Lymphoma Combination with Lenalidomide Non-Hodgkin Lymphoma Acute Lymphocytic Leukemia Solid Tumors TandAb CD33 CD3 / T-cell Acute Myeloid Leukemia Trispecific Abs Undisclosed undisclosed Multiple Myeloma *CPI = Checkpoint inhibitor Worldwide rights with Affimed Partnered program 4
5 Highlights H1-15 Raised $41 million in follow-on offering in May 2015 to enhance AFM13 and AFM11 programs and to generate further NK-cell engagers Performed pre-clinical studies of AFM13 in combination with checkpoint inhibitors (Stanford) and lenalidomide (Mayo Clinic); combination data were presented at ASCO 2015 Selected CD33/CD3 candidate for IND-enabling studies in collaboration with Amphivena/Janssen; received milestone; presented 3 posters at ASCO Published three papers: AFM13 phase 1 (BLOOD), AFM11 preclinical data (mabs) and TandAb generation (Eur. Pharm. Rev.) Received BMBF grant to support dual tumor targeting platform and development of multi-specific antibodies for multiple myeloma 5
6 Engaging NK-cells to Fight Cancer: AFM13 Credit: Joshua Stokes, St. Jude Children's Research Hospital 6
7 NK-cells: Important cells for innate immunity Significant interest by industry Lirilumab Innate/BMS IgGs TandAbs KIR2 Other cytokines AFM13 CD16A TandAbs Affimed CD16A (FcgRIIIA) TNFa IFNg Stimulation of T-cell response MK-4166 Merck GITR Urelumab PF BMS, Pfizer CD137 (4-1BB) CD319 (CS1) Elotuzumab BMS/Abbvie PD-1 NKG2a IPH2201 Innate/AZ Nivolumab Pembrolizumab BMS, Merck PD-L1 MEDI4736 MPDL3280A MSB C AZ, Roche MerckSerono/Pfizer 7
8 NK-cell engagement: Targeted single cell apoptosis induction via immune cell engagement Stage 1 Stage 2 Stage 3 Stage 4 NK-cell with CD16A receptors and tumor cell with CD30 receptors NK-cell TandAb locks NK-cell and tumor cell in close proximity and activates NK-cell NK-cell releases perforin, creating pores in tumor cell membrane through which granzyme enters, triggering caspase cascade Granzyme and caspase action trigger apoptosis of tumor cell 8
9 AFM13 Clinically most advanced NK-cell engager validating platform Potential as drug in CD30-positive lymphoma Demonstrated clinical and PD activity in heavily pretreated HL patients Data were published in Blood and ASH2014 Phase 2a initiated in r/r HL patients Maximize effect by optimized regimen and longer treatment period Very good safety, well suited for combination with wide range of other drugs CPIs and lenalidomide in preclinical investigations (Stanford University and Mayo Clinic) Study role of NK-cells in tumor environment NK-cells may influence T-cell tumor infiltration 9
10 % C h a n g e in T u m o r V o lu m e R e la tiv e to B a s e lin e AFM13: Significant synergy of AFM13 in combination with PD-1 inhibitor Ig G A F M 1 3 a n ti-c T L A -4 a n ti-p D -1 a n ti-c D A F M a n ti-c T L A -4 A F M a n ti-p D -1 A F M a n ti-c D Tumor pieces (8x8 mm) were derived from surgical specimens of a newly diagnosed CD30 + Hodgkin Lymphoma patients; Tumor pieces (8x8 mm) were xenografted and mice were randomized into 8 groups on day 28. Autologous PBMCs were infused on day 28 (2x10 6 PBMCs/mouse) i.p. Therapy with AFM13 and CPI began on day 28 and continued weekly for a total of three I.P injections. Tumor size was compared between groups on day
11 F o ld C h a n g e in In tra tu m o ra l L y m p h o c y te P o p u la tio n C o m p a re d to Ig G T re a tm e n t (d a y 5 8 ) AFM13: Increased number of tumor-infiltrating cytotoxic T-cells with AFM13/PD-1 and./ctla-4 C D 3 + /C D 8 + /IF N g + T -c e lls Ig G A F M 1 3 a C T L A -4 a P D -1 a C D A F M a C T L A -4 A F M a P D -1 A F M a C D
12 AFM13 Clinical development strategy Study initiated Phase 2, PoC r/r HL GHSG; n=40 Data on PoC Studies in planning Phase 1b/2a, TR CD30+ lymphoma Columbia; n=24 Data on dose End of Ph2 Meeting FDA Registration Study Phase 1b, + CPI r/r HL n=t.b.d. Data on combo 12
13 AFM13 Summary Encouraging phase 1 data Clinical strategy to validate AFM13 and NK-cell platform The Leukemia & Lymphoma Society provides major financial contribution Opportunity for mono- and combination therapies Multiple near-term milestones AFM13 ASCO ASH ASCO ASH ASCO Ph2a HL Monotherapy Preclin. AFM13+CPI Ph1b/2a CD30+ lymph. Funded activities Planned milestones, news releases, posters/ presentations Preclin. AFM13+Len. Ph1b HL AFM13+CPI Follow-on Manufacturing Broadening of NK-cell engager pipeline in NHL, colon/h&n, MM or GBM 13
14 Engaging T-cells to Fight Cancer: AFM11 STEVE GSCHMEISSNER/SCIENCE SOURCE 14
15 AFM11 Differentiation from BiTE Blincyto (blinatumomab) is first T-cell engager approved by FDA for treatment of ALL (12/14) AFM11 (CD19/CD3 TandAb) preclinical data (published in mabs) ~100-fold higher affinity to CD3 as compared to BiTE Low pm cytotoxicity maintained at low effector to target (E:T) ratio Prolonged t½ allows regular i.v. infusion Blincyto AFM11 MW ~55 kda ~104 kda Binding sites 1 for each, CD3 & CD19 2 for each, CD3 & CD19 Affinity to CD3 + cells 100 nm 1 nm Phase 1 dose escalation in NHL/ALL patients ongoing 15
16 AFM11 Clinical development strategy Study initiated Phase 1, Safety r/r NHL/ALL AFMD; n=30-36 Data Studies in planning Phase 1, Safety NHL (new regimen) AFMD; n=t.b.d. Data Scientific Advice Meeting FDA/EMA POC studies in NHL and/or ALL Phase 1, Safety ALL (new regimen) AFMD; n=t.b.d. Data 16
17 AFM11 Summary Phase 1 dose escalation in NHL/ALL patients initiated Endpoints: safety, activity, efficacy Drug administered by regular i.v. infusion Multiple options for differentiation from competition Indication, convenience ( CAR-T in a vial ) Multiple near term milestones ASCO ASH ASCO ASH ASCO AFM11 Ph1 NHL/ALL Ph1 NHL (new dose regimen) Funded activities Planned milestones, news releases, posters/ presentations Ph1 ALL (new dose regimen) Follow-on Strong market potential 17
18 AFM21 Summary of preclinical program EGFRvIII is a highly tumor-specific receptor variant EGFRvIII is expressed e.g. in glioma/glioblastoma, prostate, H&N, breast, lung Data update at AACR 2015 (poster presentation) 2 molecules at discovery stage EGFRvIII/CD3 TandAb TandAb candidates are potent and show efficacy in animal tumors model EGFRvIII/CD16A TandAb Molecule generation has been advanced Milestone and news flow AFM21 (T- or NK-cell) AACR ASH ASCO ASH ASCO Preclinical Development Planned milestones, news releases, posters/ presentations 18
19 Partnership with Amphivena/Janssen Achieved milestone ahead of schedule Development of a CD33/CD3 TandAb for AML Program further validates robustness of Affimed s TandAb platform Rapid identification of preclinical candidate (< 18 months) Molecules are stable, highly expressed, and display significant in vitro and in vivo cytotoxicity 2 nd milestone achieved in March 2015 triggering payment of EUR 7.5 million Corroborative evidence of direct correlation between binding affinity and potency Confirmed in translational studies (primary AML specimens) To be presented at ASCO (3 posters Abstracts 3057, 7067 & 7071) Amphivena/Janssen ASCO ASH ASCO ASH ASCO Preclinical Development Planned milestones, news releases, posters/ presentations
20 Platform development Trispecific Abs Based on tetravalent platform Results in high affinity and, importantly, in increased selectivity for malignant tissues compared to healthy tissues CD19 CD30 Healthy cell Healthy cell Cytotoxic effector cell Tumor cell Platform offers an expansion of target space Program for the therapy of multiple myeloma initiated Supported by EUR 2.4 million ($3 million) German government research grant 20
21 Use of proceeds and milestones Strong news flow in 2015 and 2016 AFM13 ASCO ASH ASCO ASH ASCO Ph2a HL Monotherapy Ph1b/2a CD30+ lymph. Preclin. AFM13+CPI Preclin. AFM13+Len. Ph1b HL AFM13+CPI Funded activities IPO Follow-on AFM11 AFM21 (T- or NK-cell) Janssen/Amphivena Discovery/ Preclin. Development Manufacturing Ph1 NHL/ALL Ph1 NHL (new dose regimen) Ph1 ALL (new dose regimen) Preclinical Development Preclinical Development Novel NK-cell engagers Trispecific Program Planned milestones, new releases, posters/ presentations
22 Q1/2015 Cash flow statement in thousands of For the three months ended March 31, 2015 Cash and Cash equivalents at the beginning of the period 39,725 FX related changes to Cash and Cash equivalents 1,269 Net cash used in operating activities (3,924) Cash Flow from investing activities (37) Cash Flow from financing activities 0 Cash and Cash equivalents as of March 31, ,033 Net proceeds of May 2015 follow-on ~33,166 Cash reach projected through H2/2017 (including this financing and additional use of proceeds of this financing) 22
23 Our strategy Maximize value from pipeline and technologies Leverage first product to establish market in key indication Develop AFM13 through approval in salvage settings in multiple CD30-positive indications and detail product through own U.S. and/or EU sales forces Salvage settings enable fast development path and cost-efficient M&S structure Scientific leadership in NK-cell engagement Position AFM13 as combination drug with CPIs and other anti-cancer agents Use pipeline and technologies to create value through both next-generation products and deal opportunities Develop AFM11 through phase 2 POC studies Advance EGFRvIII TandAbs (AFM21) in solid tumors Enhance CD16A/NK-cell TandAb pipeline Add high-value technology platform partnership 23
Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationAffimed. Developing First-in-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer
Affimed Developing First-in-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer Corporate Presentation October 2018 Forward-Looking Statements / Safe Harbor Legal notices
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationAffimed. Developing First-in-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer
Affimed Developing First-in-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer Corporate Presentation December 2018 Forward-Looking Statements / Safe Harbor Legal notices
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationAffimed. Developing First-in-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer
Affimed Developing First-in-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer Jefferies 2018 London Healthcare Conference Forward-Looking Statements / Safe Harbor Legal
More informationActualizing the Untapped Potential of the Innate Immune System
Actualizing the Untapped Potential of the Innate Immune System Affimed s Approach to Advancing Immuno-oncology January 2019 Forward-Looking Statements / Safe Harbor This presentation and the accompanying
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationAffimed 2018 Research and Development Day. December 7, 2018
Affimed 2018 Research and Development Day December 7, 2018 Forward-Looking Statements / Safe Harbor Legal notices This presentation and the accompanying oral commentary contain forward-looking statements
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationKeyzilen TM Program Update
Keyzilen TM Program Update October 11, 2016 Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties.
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationInnate Immunity-based Therapeutic Strategies Actualized through Affimed s ROCK Platform
Innate Immunity-based Therapeutic Strategies Actualized through Affimed s ROCK Platform Dr. Martin Treder CSO Affimed GmbH Innate Killer Summit, San Diego, US March 19-21, 2019 Forward-Looking Statements
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationIncyte Corporation. Hervé Hoppenot President & CEO. 34th J.P. Morgan Annual Healthcare Conference January 11, 2016
Incyte Corporation Hervé Hoppenot President & CEO 34th J.P. Morgan Annual Healthcare Conference January 11, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters
More informationTargeted Therapeutics for Inflammatory Disease Jefferies Healthcare Conference
Targeted Therapeutics for Inflammatory Disease 2016 Jefferies Healthcare Conference Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More information[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More information(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationMerus. Corporate Presentation. November 15, 2018
Merus Corporate Presentation November 15, 2018 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of
More informationCiti Global Healthcare Conference
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationBuilding a Franchise in HDV. Pegylated Interferon Lambda-1a
Building a Franchise in HDV Sarasar (lonafarnib) Pegylated Interferon Lambda-1a Forward-Looking Statements This presentation and the oral commentary contain forward-looking statements that involve substantial
More informationCOMPANY PRESENTATION. Hervé Brailly, CEO Jefferies 2014 Healthcare Conference. Page 1
COMPANY PRESENTATION Hervé Brailly, CEO Jefferies 2014 Healthcare Conference Page 1 Forward Looking Statement This document has been prepared by Innate Pharma S.A. (the Company ) solely for the purposes
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More information